Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
2.300
-0.190 (-7.63%)
At close: Mar 28, 2025, 4:00 PM
2.302
+0.002 (0.07%)
After-hours: Mar 28, 2025, 7:12 PM EDT
Biomea Fusion Employees
Biomea Fusion had 103 employees as of December 31, 2023. The number of employees increased by 20 or 24.10% compared to the previous year.
Employees
103
Change (1Y)
20
Growth (1Y)
24.10%
Revenue / Employee
n/a
Profits / Employee
-$1,398,136
Market Cap
83.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Dec 31, 2021 | 51 | 39 | 325.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BMEA News
- 5 days ago - Biomea Fusion Announces Leadership Transition - GlobeNewsWire
- 6 days ago - Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose - GlobeNewsWire
- 27 days ago - Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes - GlobeNewsWire
- 3 months ago - Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday? - Benzinga
- 3 months ago - Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes - GlobeNewsWire
- 3 months ago - Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - GlobeNewsWire
- 3 months ago - Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire